Provexis Limited was founded in 1999 by Dr Bill Mullen of Angle plc to commercialise the Fruitflow® anti-thrombotic technology discovered at the Rowett Research Institute by Professor Asim Dutta Roy.

A further technology for the treatment of Inflammatory Bowel Disease was added to the portfolio in 2003 by way of a joint venture with the University of Liverpool.

Initial funding was provided by Angle plc, Rising Stars Growth Fund and North West Equity Fund. In 2005 Provexis merged with Nutrinnovator plc, founded by the current CEO Stephen Moon, resulting in the existing AIM-listed Provexis plc entity.

Recent developments include two additions to the R&D pipeline: a technology from the University of Liverpool for the treatment of clostridium difficile; and a technology from the University of Manchester for the treatment and prevention of peptic ulcers.

In 2008 DSM Venturing, the venturing arm of the global DSM life sciences and materials sciences corporation, became the largest shareholder in Provexis.

The company has a focused strategy of discovery, development and licensing of functional food, medical food and dietary supplement technologies.